⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7302534 | 1.00 | — | — | |
| SCHEMBL10890162 | 1.00 | OR51E2 (0.43) | — | |
| SCHEMBL7488763 | 1.00 | — | — | |
| SCHEMBL1931750 | 0.90 | SLC1A3 (0.40) | — | |
| SCHEMBL3353915 | 0.90 | SLC1A3 (0.40) | — | |
| SCHEMBL7495280 | 0.90 | SLC1A3 (0.40) | — | |
| SCHEMBL1931748 | 0.90 | SLC1A3 (0.40) | — | |
| SCHEMBL3346213 | 0.90 | SLC1A3 (0.40) | — | |
| SCHEMBL2164847 | 0.88 | SLC1A3 (0.42) | — | |
| SCHEMBL2164841 | 0.88 | SLC1A3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115103691-B | Pharmaceutical composition containing antibody drug conjugate and application thereof | 苏州盛迪亚生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119185572-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118903456-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118806924-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-112512591-B | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240132515-A1 | TOXIN MOLECULE SUITABLE FOR ANTIBODY-DRUG CONJUGATE | MINGHUI PHARMACEUTICAL (HANGZHOU) LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2024074848-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| EP-4286389-A1 | TOXIN MOLECULE SUITABLE FOR ANTIBODY-DRUG CONJUGATE | Minghui Pharmaceutical (Hangzhou) Limited (CN) | 2023-12-06 | — | — | EP | disclosed |
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0684240-B1 | Hydroxamic acid derivatives with three ring substituents | HOFFMANN LA ROCHE (CH) | 2000-08-02 | — | — | EP | disclosed |
| US-6066662-A | USE IN CONTROL OR PREVENTION OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS OR IN THE TREATMENT OF INVASIVE TUMOURS, ATHEROSCLEROSIS OR MULTIPLE SCLEROSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5731441-A | COLLAGENASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1998-03-24 | — | — | US | disclosed |
| US-5710167-A | Hydroxamic acid derivatives with tricyclic substitution for treating degenerative joint diseases | HOFFMANN-LA ROCHE INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5698690-A | COLLAGENASE INHIBITORS; TREATMENT OF DEGENERATIVE JOINT DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5614625-A | COLLAGENASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0763013-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033709-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-12-14 | — | — | WO | disclosed |
| EP-0684240-A1 | Hydroxamic acid derivatives with tricyclic substitution | F. HOFFMANN-LA ROCHE AG (CH) | 1995-11-29 | — | — | EP | disclosed |